DEF: Profusa Seeks Shareholder OK for Capital, Share Increase

Profusa, Inc. is calling a Special Meeting of Stockholders to approve a significant convertible note financing and an increase in authorized common stock to support future growth and capital needs.

Summary

• A Special Meeting of Stockholders is scheduled for October 7, 2025, to vote on two key proposals.
• Proposal 1 seeks approval for the potential issuance of common stock exceeding 19.99% of outstanding shares upon conversion of senior secured convertible notes, as required by Nasdaq Listing Rule 5635(d).
• The convertible notes facility with Ascent Partners Fund LLC is for an aggregate principal amount of up to $22,222,222, purchased for up to $20,000,000 (reflecting a 10% original issue discount).
• An initial note of $10,000,000 principal amount was issued for $9,000,000, maturing 18 months from the IPO closing, with a conversion price based on the lower of $10 or 95% of the lowest 10-day VWAP, subject to down-round and most-favored nation protections.
• The notes accrue interest at 10% per annum, with a minimum interest amount equal to 10% of the principal, and a default interest rate of 24% per annum.
• The financing is structured in four tranches, with the Third Tranche requiring stockholder approval.
• Proposal 2 requests approval to amend the company's certificate of incorporation to increase the authorized number of common stock shares from 300,000,000 to 600,000,000.
• This increase is necessary to support the conversion of the convertible notes, an existing $100,000,000 equity line of credit (ELOC) with Ascent Partners Fund LLC, milestone earn-out shares, warrant exercises, and future equity incentive plans.
• As of the record date, September 22, 2025, 40,859,307 shares of common stock were outstanding.
• The Board of Directors recommends voting FOR both proposals, stating they are advisable and in the best interests of the company and its stockholders.

Sentiment

Score: 6

Explanation: The filing outlines crucial steps for securing necessary capital and expanding the company's equity capacity, which are positive for long-term viability and growth. However, the significant potential for dilution from the convertible notes and the increase in authorized shares, coupled with the terms of the financing (e.g., 10% OID, 24% default interest), suggest a financing under potentially challenging conditions. The delay in the S-1 filing also adds a minor negative note. The overall sentiment is cautiously positive, acknowledging the necessity of these actions despite their dilutive impact.

Positives

• Secures up to $20,000,000 in near-term capital through senior secured convertible notes, with minimal closing contingencies and no cash interest payments prior to maturity.
• The financing structure, with tranches, allows the company to match capital deployment with operational milestones and market conditions, preserving strategic flexibility.
• Approval of the authorized share increase provides essential equity capacity for future financings, acquisitions, and growth transactions, including the $100,000,000 equity line of credit and equity incentive plans.
• The Board believes that deploying this capital will accelerate commercialization, strengthen the balance sheet, and pursue strategic initiatives, creating long-term stockholder value.

Negatives

• Potential for significant dilution to existing stockholders' voting and economic interests, as the full conversion of the PIPE Convertible Notes could result in the issuance of approximately 222,222,222 shares.
• The conversion price is subject to downward adjustment based on market volume-weighted average price (VWAP), which could lead to even greater dilution.
• The terms of the convertible notes, including a 10% original issue discount and a 24% default interest rate, indicate a financing under potentially less favorable conditions.
• Failure to approve the proposals would severely constrain the company's ability to raise capital, satisfy contractual obligations, and pursue growth strategies, potentially leading to defaults or monetary penalties.

Risks

• Failure to obtain stockholder approval for the Convertible Notes Proposal would cap conversions at 19.99% of outstanding shares, potentially forcing the company to seek alternative, more expensive capital or renegotiate financing terms.
• Non-approval of the Authorized Shares Proposal could prevent the company from satisfying contractual obligations to issue shares under the convertible notes, ELOC, or warrants, triggering default provisions or forced cash settlements.
• Inability to increase authorized shares would severely limit the company's flexibility to raise additional capital through equity, impairing liquidity, growth, and commercialization strategies.
• The company may be forced to forego or delay strategic acquisitions or partnerships requiring equity consideration if authorized shares are not increased.
• Diminished flexibility to grant equity-based compensation could hinder the company's ability to attract and retain key employees and directors.

Future Outlook

The company's strategic objective is to pursue future financings, acquisitions, and other growth transactions. The Board believes that approving the proposals will position the company to deploy capital to accelerate commercialization, strengthen the balance sheet, and pursue strategic initiatives, ultimately creating long-term stockholder value.

Management Comments

• Our Board believes that the approval of the proposals are advisable and in the best interests of the Company and its stockholders and recommends that you vote FOR each Proposal.
• On behalf of the Board of Directors and management, it is my pleasure to express our appreciation for your continued support.

Industry Context

The company's actions to secure financing and expand its capital structure are typical for growth-oriented companies, particularly those that have recently completed a business combination and are focused on commercialization. The need for substantial capital to fund strategic initiatives, acquisitions, and equity incentives is common in the life sciences or technology sectors where Profusa operates, reflecting a standard approach to scaling operations and market presence.

Corporate Governance

Related Party Transactions

• Ascent Partners Fund LLC is a PIPE Investor, the counterparty for the senior secured convertible notes, and the provider of the $100,000,000 committed equity line of credit (ELOC). Ascent Partners Fund LLC beneficially owns 8.1% of the company's common stock.
• NorthView Sponsor I, LLC, managed by directors Fred Knechtel and Jack Stover, beneficially owns 19.0% of the company's common stock.

Stakeholder Impact

• **Shareholders:** Face potential significant dilution of voting rights and economic interests due to the conversion of notes and future equity issuances. However, approval secures critical capital for company operations and growth, mitigating risks of default and limited strategic flexibility.
• **Employees and Directors:** The increase in authorized shares provides the company with greater flexibility to grant equity-based compensation, which is vital for attracting, retaining, and incentivizing key personnel.
• **Creditors:** Ascent Partners Fund LLC, as a senior secured convertible noteholder, benefits from a security interest in substantially all of the company's assets, enhancing their position as a creditor.

Next Steps

• Stockholders will vote on the Convertible Notes Proposal and the Proposal to Increase Authorized Shares at the Special Meeting on October 7, 2025.
• If approved, the company will proceed with the potential issuance of shares upon conversion of the PIPE Convertible Notes and file an amendment to its certificate of incorporation to increase authorized shares.
• The company will use reasonable best efforts to have the S-1 registration statement, with an amended filing date of September 14, 2025, declared effective within 45-60 days of filing.
• Future tranches of the convertible notes are subject to various conditions, including stockholder approval for the Third Tranche.
• The company plans to deploy capital to accelerate commercialization, strengthen the balance sheet, and pursue strategic initiatives.
• The company intends to pursue future financings, acquisitions, and other growth transactions.

Key Dates

Recommendation

The company is undertaking crucial steps to secure financing and expand its capital structure, which are essential for its operational continuity and strategic growth, including commercialization. While these actions are vital for the company's long-term viability, the significant potential for dilution from the convertible notes and the proposed increase in authorized shares introduces considerable risk to existing shareholders' equity value. The terms of the convertible notes, including a 10% original issue discount and a 24% default interest rate, suggest a financing under potentially challenging market conditions. The delay in the S-1 filing also indicates some operational hurdles. Given the balance between securing essential capital for future growth and the immediate dilutive impact, a 'hold' recommendation is appropriate. Investors should closely monitor the execution of the financing tranches, the company's progress on commercialization, and the actual dilutive effects as shares are issued.

Keywords

Profusa, Convertible Notes, Authorized Shares, Nasdaq Listing Rule 5635(d), Capital Raise, Equity Financing, Shareholder Meeting, Dilution, Corporate Governance, Stock, PIPE Financing, Equity Line of Credit